CMOs are working hard to improve performance by investigating new technologies for filtration and purification. Downstream processing problems are not unique to CMOs, of course. It seems, however, ...

Westford USA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- According to SkyQuest, the growing popularity and rising demand for biopharmaceuticals, including vital products such as monoclonal antibodies, vaccines ...

Dublin, Feb. 21, 2024 (GLOBE NEWSWIRE) -- The "Downstream Processing Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Drug development and manufacturing have undergone a seismic shift in the last two decades, 1 from blockbuster small molecules to highly personalized biologics 2 and cell and gene therapies. Because ...

Lindian Resources has secured 100 per cent ownership of a key Kazakhstan-based rare earth processing plant, accelerating its push to become a vertically integrated producer.